Title
Results from a phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab
Document Type
Presentation
Publication Date
11-8-2022
Keywords
oregon; portland; chiles
Clinical Institute
Cancer
Department
Oncology
Recommended Citation
Sanborn, Rachel E. and See all authors in comments, "Results from a phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab" (2022). Articles, Abstracts, and Reports. 6983.
https://digitalcommons.providence.org/publications/6983
Comments
Sanborn R, Gabrail N, Carneiro B, O'Hara M, Bordoni R, Gordon M, Khalil D, Hauke R, Taglienti C, Rogalski M, Styles R, Alvarado D, Maurer D, Crew L, Keler T, Yellin M. SITC Annual Meeting; November 8-12; Boston, MA. 2022;10(Suppl 2): 596. doi: 10.1136/jitc-2022-SITC2022.0596.